- Home
- ABEO
as of 01-26-2026 3:41pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 281.0M | IPO Year: | 1980 |
| Target Price: | $18.20 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.93 - $7.54 | Next Earning Date: | 03-19-2026 |
| Revenue: | $400,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1589.77% |
AI-Powered ABEO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
SVP, Chief Legal Officer
Avg Cost/Share
$5.33
Shares
13,578
Total Value
$72,382.96
Owned After
451,134
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$5.33
Shares
18,666
Total Value
$99,506.58
Owned After
568,560
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$5.33
Shares
69,832
Total Value
$372,267.41
Owned After
1,460,408
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$5.29
Shares
12,610
Total Value
$66,657.72
Owned After
318,619
SEC Form 4
Director
Avg Cost/Share
$5.23
Shares
13,500
Total Value
$70,573.95
Owned After
48,752
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$5.31
Shares
25,000
Total Value
$132,740.00
Owned After
1,460,408
SEC Form 4
Director
Avg Cost/Share
$4.74
Shares
15,000
Total Value
$71,167.50
Owned After
48,752
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| O'Malley Brendan M. | ABEO | SVP, Chief Legal Officer | Jan 22, 2026 | Sell | $5.33 | 13,578 | $72,382.96 | 451,134 | |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Jan 22, 2026 | Sell | $5.33 | 18,666 | $99,506.58 | 568,560 | |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Jan 22, 2026 | Sell | $5.33 | 69,832 | $372,267.41 | 1,460,408 | |
| Vasanthavada Madhav | ABEO | Chief Commercial Officer | Jan 22, 2026 | Sell | $5.29 | 12,610 | $66,657.72 | 318,619 | |
| Alvino Mark | ABEO | Director | Jan 21, 2026 | Sell | $5.23 | 13,500 | $70,573.95 | 48,752 | |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Dec 29, 2025 | Sell | $5.31 | 25,000 | $132,740.00 | 1,460,408 | |
| Alvino Mark | ABEO | Director | Nov 13, 2025 | Sell | $4.74 | 15,000 | $71,167.50 | 48,752 |
Compare ABEO vs Leading Stocks
See how ABEO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.